Zika Vaccine Shows Protective Efficacy in Monkeys
News Dec 06, 2018 | Original story from the University of Hawai'i at Manoa
Zika virus results in neurological complications in babies born from infected mothers. The immunogenicity and protective efficacy of a recombinant subunit vaccine candidate has been demonstrated in mice, and in long-tailed macaques (Macaca fascicularis, also known as the crab-eating macaque). Image credit: Mr. Theklan.
Researchers led by Dr. Alex Lehrer at the University of Hawaiʻi (UH) medical school have successfully developed a vaccine candidate for the Zika virus, showing that it is effective in protecting both mice and now monkeys from the infection.
Demonstrating the effectiveness of the vaccine candidate in monkeys (non-human primates) is an important milestone because it typically predicts the vaccine will work in humans, enabling further clinical development.
A strong global initiative to battle Zika has produced more than 30 vaccine candidates since outbreaks in 2015-2016 in Brazil linked the infection in some pregnant women to severe birth defects in their newborns. Zika is spread by the bite of infected mosquitos and through sex.
There is no treatment or cure for Zika virus infection nor is any vaccine currently approved for public use.
The proposed vaccine reported by scientists at the UH John A. Burns School of Medicine (JABSOM) in the journals Frontiers in Immunology and mSphere, an open access journal of the American Society for Microbiology, is a recombinant subunit vaccine that uses only a small part (protein) of the Zika virus, produced in insect cells.
“We believe our vaccine candidate shows much promise particularly as it showed to require only two immunizations given three weeks apart and is a potentially safer alternative to other candidates already in clinical trials,” said Dr. Axel Lehrer, JABSOM (Assistant) Professor of Tropical Medicine and Infectious Disease.
Lehrer thinks the vaccine his team proposes might be safer that other candidate vaccines, especially keeping in mind that pregnant women constitute a significant part of the target population for a Zika vaccine.
The research team at JABSOM included two senior graduate students who served as lead authors of the scientific research papers. Liana Medina, whose early training was directly supported by a National Institutes of Health Diversity in Health-Related Research grant, and Honolulu native Albert To are the graduate student lead authors.
Honolulu-based Hawai’i Biotech is a key partner in the vaccine development project with UH. Two of their scientists, Dr. Jaime Horton and David Clements, contributed to the most recent publication demonstrating vaccine efficacy in monkeys, along with collaborators from Bioqual Inc. of Rockville, Maryland, and the Department of Diagnostic Medicine/Pathobiology, Biosecurity Research Institute, College of Veterinary Medicine, at Kansas State University.
“The intense search for a Zika remedy since early 2016 has required us to be agile, and we believe our vaccine candidate research demonstrates that such quick-turnaround results can be achieved in academic and scientific partnerships here in Hawai’i,” said Dr. Lehrer. “It is incredibly gratifying that two of the scientists we are training to be the future of biomedical science played key roles in gathering, analyzing and reporting their conclusions. We hope Hawai’i’s citizens find that as inspiring as we do.”
Graduate student scientist and research co-author Liana Medina said there were chances to develop new skills at every step along the way. “Having the opportunity to see the vaccine’s development from its very first stages as Zika E protein being produced by Dr. Kenji Obadia, at the time also a student in our department, to a vaccine that is efficacious and safe in animal models was a unique learning experience. Being a part of the process allowed me grow as a student in this field,” said Medina.
Fellow graduate student and co-author Albert To said the team’s results “put us on the world-stage and highlight the talent we have here in Hawaiʻi.” He said, “Being involved with this project has given me a glimpse of the type of research and results needed to progress an idea to a potential preventative therapy used by thousands of people worldwide.”
This article has been republished from materials provided by the University of Hawai'i at Manoa. Note: material may have been edited for length and content. For further information, please contact the cited source.
Medina, L. O., To, A., Lieberman, M. M., Wong, T. A., Namekar, M., Nakano, E., . . . Lehrer, A. T. (2018). A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates. Frontiers in Immunology, 9. doi:10.3389/fimmu.2018.02464
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
3rd Annual DIGI-TECH PHARMA 2019 Conference & Expo
May 21 - May 22, 2019